Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Gregory Elliott

Showing results (91-100 of 111) with videos related to

Pageof 12
Sort By:
Pulmonary Circulation|September 10, 2013
Circulating angiogenic modulatory factors predict survival and functional class in pulmonary arterial hypertensionRajeev Malhotra, Samuel Paskin-Flerlage, Roham T Zamanian, et al.
Journal of the American College of Cardiology|June 27, 2020
Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill PatientsAlex C Spyropoulos, Walter Ageno, Gregory W Albers, et al.
Circulation|April 15, 2009
Physician alerts to prevent symptomatic venous thromboembolism in hospitalized patientsGregory Piazza, Erin J Rosenbaum, William Pendergast, et al.
Pulmonary Circulation|May 18, 2019
United States Pulmonary Hypertension Scientific Registry (USPHSR): rationale, design, and clinical implicationsC Gregory Elliott, Eric D Austin, David Badesch, et al.
Thrombosis and Haemostasis|February 5, 2016
The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implicationsGary E Raskob, Alex C Spyropoulos, Julie Zrubek, et al.
The European Respiratory Journal|April 4, 2015
Validation of two predictive models for survival in pulmonary arterial hypertensionOlivier Sitbon, Raymond L Benza, David B Badesch, et al.
Chest|August 29, 2020
United States Pulmonary Hypertension Scientific Registry: Baseline CharacteristicsJessica B Badlam, David B Badesch, Eric D Austin, et al.
TH Open : Companion Journal to Thrombosis and Haemostasis|September 1, 2022
Rivaroxaban Plus Aspirin for Extended Thromboprophylaxis in Acutely Ill Medical Patients: Insights from the MARINER TrialAlex C Spyropoulos, Mark Goldin, Walter Ageno, et al.
Journal of the American Heart Association|October 7, 2022
Benefit-Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical IllnessGary E Raskob, Walter Ageno, Gregory Albers, et al.
Circulation|April 7, 2022
Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER TrialsAlex C Spyropoulos, Gary E Raskob, Alexander T Cohen, et al.
Pageof 12

Showing results (91-100 of 111) with videos related to

Sort By:
Pageof 12
Pulmonary Circulation|September 10, 2013
Circulating angiogenic modulatory factors predict survival and functional class in pulmonary arterial hypertensionRajeev Malhotra, Samuel Paskin-Flerlage, Roham T Zamanian, et al.
Journal of the American College of Cardiology|June 27, 2020
Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill PatientsAlex C Spyropoulos, Walter Ageno, Gregory W Albers, et al.
Circulation|April 15, 2009
Physician alerts to prevent symptomatic venous thromboembolism in hospitalized patientsGregory Piazza, Erin J Rosenbaum, William Pendergast, et al.
Pulmonary Circulation|May 18, 2019
United States Pulmonary Hypertension Scientific Registry (USPHSR): rationale, design, and clinical implicationsC Gregory Elliott, Eric D Austin, David Badesch, et al.
Thrombosis and Haemostasis|February 5, 2016
The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implicationsGary E Raskob, Alex C Spyropoulos, Julie Zrubek, et al.
The European Respiratory Journal|April 4, 2015
Validation of two predictive models for survival in pulmonary arterial hypertensionOlivier Sitbon, Raymond L Benza, David B Badesch, et al.
Chest|August 29, 2020
United States Pulmonary Hypertension Scientific Registry: Baseline CharacteristicsJessica B Badlam, David B Badesch, Eric D Austin, et al.
TH Open : Companion Journal to Thrombosis and Haemostasis|September 1, 2022
Rivaroxaban Plus Aspirin for Extended Thromboprophylaxis in Acutely Ill Medical Patients: Insights from the MARINER TrialAlex C Spyropoulos, Mark Goldin, Walter Ageno, et al.
Journal of the American Heart Association|October 7, 2022
Benefit-Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical IllnessGary E Raskob, Walter Ageno, Gregory Albers, et al.
Circulation|April 7, 2022
Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER TrialsAlex C Spyropoulos, Gary E Raskob, Alexander T Cohen, et al.
Pageof 12